EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase II)

Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia

Amir T Fathi, Alexander E Perl, Geoffrey G Fell, Brian A Jonas, Brittany K Ragon, Alice S Mims, Uma Borate, Gabriel N Mannis, Karen Quillen, Maximilian Stahl, Brandon J Aubrey, Paul Koller und 29 weitere

New England Journal of Medicine · 03.09.2026 · 395 (9) · 845-858

DOI: 10.1056/nejmoa2602804 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 03.09.2026. Verfasst von Amir T Fathi und 40 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Cancer Institute at Massachusetts General Hospital, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Induction Chemotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicInduction ChemotherapyLeukemia, Myeloid, AcuteSulfonamidesAdultAgedFemaleHumansMiddle AgedNucleophosminMutationProgression-Free SurvivalFollow-Up StudiesMaleYoung Adult

Substanzen

AzacitidineBridged Bicyclo Compounds, HeterocyclicNPM1 protein, humanNucleophosminSulfonamidesvenetoclax

Autor:innen und Institutionen

  • Mass General Brigham Cancer Institute at Massachusetts General Hospital, Harvard Medical School, Boston.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Dana-Farber Cancer Institute, Boston.
  • University of California, Davis, School of Medicine, Sacramento.
  • Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC.
  • Ohio State University Comprehensive Cancer Center, Columbus.

ORCID-Profile: Christopher S Hourigan

Zitieren

APA

Fathi, A. T., Perl, A. E., Fell, G. G., Jonas, B. A., Ragon, B. K., Mims, A. S., Borate, U., Mannis, G. N., Quillen, K., Stahl, M., Aubrey, B. J., Koller, P., Artz, A. S., Al Malki, M. M., Stein, A. S., Marcucci, G., Peters, M. L. B., Graubert, T. A., Westervelt, P., …, & Aldoss, I. (2026). Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia. New England Journal of Medicine, 395(9), 845-858. https://doi.org/10.1056/nejmoa2602804

Vancouver

Fathi AT, Perl AE, Fell GG, Jonas BA, Ragon BK, Mims AS, et al. Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia. New England Journal of Medicine. 2026;395(9):845-858. doi:10.1056/nejmoa2602804

BibTeX
@article{Fathi2026,
  author = {Fathi, Amir T and Perl, Alexander E and Fell, Geoffrey G and Jonas, Brian A and Ragon, Brittany K and Mims, Alice S and Borate, Uma and Mannis, Gabriel N and Quillen, Karen and Stahl, Maximilian and Aubrey, Brandon J and Koller, Paul and Artz, Andrew S and Al Malki, Monzr M and Stein, Anthony S and Marcucci, Guido and Peters, Mary Linton B and Graubert, Timothy A and Westervelt, Peter and Amrein, Philip C and Hock, Hanno R and Brunner, Andrew M and Hobbs, Gabriela and Narayan, Rupa and Lee, Michelle H and Miller, Peter G and Watson, Alyssa L and Hao, Richard and Marola, Abigail C and Lombardi-Story, Jennifer and Dhaver, Shilton and Grunwald, Michael R and Chen, Yi-Bin and Weinstock, Matthew J and Matthews, Andrew H and McGovern, Ian and Wood, Brent L and Hourigan, Christopher S and Neuberg, Donna S and El-Jawahri, Areej and Aldoss, Ibrahim},
  title = {Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {9},
  pages = {845--858},
  doi = {10.1056/nejmoa2602804}
}
Kostenlos starten →